Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Sofosbuvir subsidised in Australia for hepatitisC

Sofosbuvir subsidised in Australia for hepatitisC PharmacoEconomics & Outcomes News 784, p37 - 12 Aug 2017 Sofosbuvir subsidised in Australia for hepatitis C Sofosbuvir (Epclusa) will be subsidised in Australia for the treatment of hepatitis C from 1 August 2017, via the Pharmaceutical Benefits Scheme (PBS). Sofosbuvir is the first of the new direct acting antivirals that can be used in the treatment of patients with any genotype of hepatitis and has an expected success rate of 90%. Up to 200 000 Australians are infected with hepatitis C, with approximately 800 people dying from the infection each year. The newly announced government funding will reduce the treatment cost to the patient to a maximum of $A38.80 per month, with the concessional price being just $6.30, compared with unsubsidised costs of over $20 000 per treatment. "Eliminating hepatitis C from Australia will take a coordinated effort from GPs, specialists, nurses, patients and the Government", commented Minister for Health, the Hon. Greg Hunt MP. "Today is World Hepatitis Day and I want to reiterate the Government’s commitment to eliminate hepatitis C in Australia by 2030". Over 42 000 Australians have benefited from PBS- subsidised medicine for chronic hepatitis C since Australia became one of the first countries http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Sofosbuvir subsidised in Australia for hepatitisC

PharmacoEconomics & Outcomes News , Volume 784 (1) – Aug 12, 2017
Download PDF
1 page

Sofosbuvir subsidised in Australia for hepatitisC

Abstract

PharmacoEconomics & Outcomes News 784, p37 - 12 Aug 2017 Sofosbuvir subsidised in Australia for hepatitis C Sofosbuvir (Epclusa) will be subsidised in Australia for the treatment of hepatitis C from 1 August 2017, via the Pharmaceutical Benefits Scheme (PBS). Sofosbuvir is the first of the new direct acting antivirals that can be used in the treatment of patients with any genotype of hepatitis and has an expected success rate of 90%. Up to 200 000 Australians are infected with hepatitis...
Loading next page...
1
 
/lp/springer_journal/sofosbuvir-subsidised-in-australia-for-hepatitisc-JM49BaSXX2

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
DOI
10.1007/s40274-017-4248-5
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 784, p37 - 12 Aug 2017 Sofosbuvir subsidised in Australia for hepatitis C Sofosbuvir (Epclusa) will be subsidised in Australia for the treatment of hepatitis C from 1 August 2017, via the Pharmaceutical Benefits Scheme (PBS). Sofosbuvir is the first of the new direct acting antivirals that can be used in the treatment of patients with any genotype of hepatitis and has an expected success rate of 90%. Up to 200 000 Australians are infected with hepatitis C, with approximately 800 people dying from the infection each year. The newly announced government funding will reduce the treatment cost to the patient to a maximum of $A38.80 per month, with the concessional price being just $6.30, compared with unsubsidised costs of over $20 000 per treatment. "Eliminating hepatitis C from Australia will take a coordinated effort from GPs, specialists, nurses, patients and the Government", commented Minister for Health, the Hon. Greg Hunt MP. "Today is World Hepatitis Day and I want to reiterate the Government’s commitment to eliminate hepatitis C in Australia by 2030". Over 42 000 Australians have benefited from PBS- subsidised medicine for chronic hepatitis C since Australia became one of the first countries

Journal

PharmacoEconomics & Outcomes News – Springer Journals

Published: Aug 12, 2017

There are no references for this article.